Vitamin D Deficiency: Pathophysiology, Clinical Manifestations, and Treatment

← Back to Chapters

Vitamin D deficiency represents a significant global public health concern with profound implications across multiple organ systems, including the central nervous system. This article provides an in-depth examination of vitamin D pathophysiology, its role in psychiatric and neurological health, age-specific clinical manifestations, and contemporary evidence-based therapeutic approaches for psychiatrists and medical practitioners.

Historical Perspective and Epidemiology

While rickets, the classic manifestation of severe vitamin D deficiency, has been recognized since the 17th century, our understanding of vitamin D's systemic importance has evolved dramatically over the past two decades. The landmark observations linking vitamin D to immunological function, cardiovascular health, and psychiatric disorders emerged only in the 2000s, representing a paradigm shift in nutritional medicine.

The historical narrative begins with the industrial revolution in Northern Europe, where urban smog and indoor working conditions precipitated widespread rickets epidemics. Fortification programs in the early 20th century—particularly milk fortification in the United States and Scandinavia—temporarily ameliorated the problem. However, contemporary epidemiological surveys reveal that approximately 1 billion individuals worldwide have insufficient vitamin D levels, with prevalence rates ranging from 30-50% in developed nations and exceeding 80% in Middle Eastern and Asian populations.

Contemporary deficiency is driven by multiple factors: reduced outdoor sun exposure due to urbanization, occupational constraints, latitudinal residence in northern climates, protective sun exposure behaviors, darkly pigmented skin in high-latitude populations, and increasingly restrictive dietary practices. Unlike historical rickets, modern deficiency often occurs insidiously without skeletal manifestations, leading to delayed recognition and widespread subclinical disease.

Pathophysiology of Vitamin D Metabolism and Activation

A comprehensive understanding of vitamin D deficiency pathophysiology requires appreciation of the complex metabolic pathway and multi-system effects of this secosteroid hormone.

Figure 1: Multi-step vitamin D activation pathway from cutaneous synthesis to active hormone

Production and Activation

Vitamin D metabolism involves a series of sequential hydroxylation reactions. Cutaneous synthesis of vitamin D3 (cholecalciferol) occurs when 7-dehydrocholesterol in the epidermis undergoes photoisomerization upon exposure to ultraviolet B radiation (UVB, 290-315 nm wavelength). This process is remarkably efficient: approximately 10-30 minutes of midday sun exposure on exposed skin in fair-skinned individuals generates 10,000-20,000 IU of vitamin D3. However, this process is significantly attenuated by skin pigmentation, geographical latitude, seasonal variation, and protective sun exposure behaviors.

Following hepatic absorption, vitamin D3 undergoes 25-hydroxylation by hepatic 25-hydroxylase (CYP2R1 and CYP27A1) to form 25-hydroxyvitamin D [25(OH)D], commonly called calcifediol. This metabolite represents the primary circulating storage form and serves as the most reliable indicator of vitamin D status. Importantly, 25(OH)D has minimal biological activity; its half-life of 2-3 weeks permits reliable measurement reflecting cumulative vitamin D exposure over preceding 8-12 weeks.

The final activation step occurs in renal proximal tubular epithelium via 1α-hydroxylase (CYP27B1), producing the potent active metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D], also termed calcitriol. This metabolite possesses approximately 500-1000 times the biological potency of 25(OH)D and exhibits a half-life of only 4-6 hours, necessitating tightly regulated production. Circulating 1,25(OH)2D levels remain relatively constant despite wide variation in 25(OH)D levels due to sophisticated homeostatic feedback mechanisms.

Mechanism of Vitamin D Action

The 1,25(OH)2D hormone exerts its effects primarily through nuclear vitamin D receptor (VDR) activation. The VDR is a ligand-activated transcription factor belonging to the steroid hormone receptor superfamily. Upon ligand binding, VDR heterodimerizes with retinoid X receptor (RXR) and binds to specific DNA sequences (vitamin D response elements, VDREs) in target gene promoters, initiating transcription of approximately 200 vitamin D-responsive genes.

Beyond genomic signaling, emerging evidence demonstrates rapid non-genomic effects mediated by membrane-associated VDR (mVDR), resulting in second-messenger activation (calcium influx, PKC, MAPK pathways) within seconds to minutes. This dual mechanism—both slow genomic and rapid non-genomic effects—provides flexibility in 1,25(OH)2D signaling across tissues. Critically, VDR expression is distributed throughout the central nervous system, including hippocampus, prefrontal cortex, and midbrain dopaminergic regions, establishing biological plausibility for psychiatric manifestations of deficiency.

Regulatory Mechanisms

Serum 1,25(OH)2D concentration is exquisitely regulated by multiple feedback mechanisms. Elevated 1,25(OH)2D directly suppresses renal 1α-hydroxylase activity via product inhibition while simultaneously inducing 24-hydroxylase (CYP24A1), which catabolizes both 25(OH)D and 1,25(OH)2D to inactive metabolites. Serum phosphate and fibroblast growth factor 23 (FGF23)—a phosphaturic hormone—also regulate 1α-hydroxylase activity. In vitamin D deficiency states, reduced 1,25(OH)2D-mediated FGF23 suppression leads to FGF23 elevation, which independently inhibits 1α-hydroxylase, creating a potentially pathological feedback loop in severe deficiency.

Age-Specific Clinical Manifestations and Pathophysiological Effects

Vitamin D deficiency exhibits distinctly different clinical phenotypes across the lifespan due to differing physiological priorities, skeletal maturity status, and systemic demands.

Pediatric and Adolescent Populations

In children and adolescents, vitamin D deficiency primarily manifests through impaired mineralization of the growing skeleton. The pathophysiological mechanism involves secondary hyperparathyroidism: reduced intestinal calcium absorption in deficient states triggers parathyroid hormone (PTH) elevation, which mobilizes skeletal calcium through increased osteoclastic resorption. This chronic PTH stimulation in the context of inadequate 1,25(OH)2D-mediated bone mineralization results in rickets—a condition characterized by disorganized growth plate morphology, impaired osteoid mineralization, and skeletal deformity.

Beyond skeletal manifestations, pediatric vitamin D deficiency has significant neurodevelopmental implications. The developing brain exhibits high VDR expression and depends upon vitamin D for:

• Calcium homeostasis: Essential for synaptic plasticity, neurotransmitter release, and action potential propagation
• Neurotrophic support: Vitamin D upregulates nerve growth factor (NGF) and other neurotrophic factors critical for axonal extension and dendritic arborization
• Neuroinflammation regulation: VDR signaling suppresses pro-inflammatory cytokines (TNF-α, IL-6) and promotes regulatory T cell differentiation, reducing neuroinflammatory burden
• Dopaminergic development: Vitamin D regulates tyrosine hydroxylase expression and dopamine signaling, with implications for reward processing and motivation

Epidemiological studies demonstrate associations between maternal vitamin D insufficiency during pregnancy and increased autism spectrum disorder risk, though causality remains unestablished. Population-level studies suggest childhood vitamin D deficiency associates with increased ADHD and depression symptomatology, though confounding variables (sun exposure, physical activity, socioeconomic status) complicate interpretation.

Adult Populations

Adult vitamin D deficiency presents a clinically subtle phenotype that has emerged as a primary concern for psychiatrists and medical practitioners. Unlike children with overt rickets, adults develop insidious multi-system dysfunction without obvious skeletal disease. The pathophysiological mechanisms driving adult disease differ from pediatric rickets:

Bone and Mineral Metabolism: Adults maintain relatively normal serum calcium through compensatory PTH elevation, yet this chronic hyperparathyroid state has substantial consequences. Persistently elevated PTH drives ongoing osteoclastic bone resorption without adequate osteoblastic mineralization, resulting in accelerated bone turnover, reduced bone mineral density, and elevated fracture risk. This process occurs silently without symptoms until fracture occurs. The underlying pathophysiology involves:

• Impaired intestinal calcium absorption (reduced VDR and calcium-binding protein expression in enterocytes)
• Secondary hyperparathyroidism driving skeletal resorption
• Reduced osteoid mineralization even in adults with adequate PTH-driven calcium mobilization
• Accelerated bone turnover with negative mineral balance

Muscular and Neuromuscular Effects: Vitamin D deficiency produces both direct muscular effects and indirect consequences of hypocalcemia. Direct mechanisms include:

• Type II muscle fiber dysfunction: VDR expression in skeletal muscle is concentrated in type II (fast, glycolytic) fibers. Deficiency impairs calcium handling in these fibers, reducing power output and fatigue resistance
• Calcium-dependent contractility: Deficiency-induced hypocalcemia directly impairs excitation-contraction coupling
• Myositis pathways: Deficiency may unmask or exacerbate myopathic processes through altered inflammatory signaling

These mechanisms manifest clinically as proximal muscle weakness, diffuse myalgias, elevated risk of falls, and in severe deficiency, acute hypocalcemic tetany. Notably, vitamin D supplementation in deficient adults restores muscle strength within 3-6 months, suggesting reversibility of these effects.

Psychiatric and Neurological Manifestations: The psychiatric implications of adult vitamin D deficiency have assumed increasing clinical importance. Multiple plausible neurobiological mechanisms link deficiency to mood and cognitive disorders:

Figure 2: Multifactorial CNS effects of vitamin D involving monoamine signaling, calcium homeostasis, neuroimmunity, and neurotrophy

Monoamine Neurotransmitter Dysfunction: Vitamin D regulates expression of enzymes essential for dopamine and serotonin synthesis. Tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis, contains VDREs in its promoter region; vitamin D deficiency reduces hippocampal and prefrontal cortical TH expression. Similarly, vitamin D deficiency correlates with reduced serotonin transporter availability in multiple brain regions. These mechanisms provide a biological foundation for the association between deficiency and depressive symptoms, anhedonia, and motivational impairment.

Calcium Homeostasis and Synaptic Dysfunction: Beyond monoamine effects, deficiency-induced hypocalcemia directly impairs synaptic transmission. Calcium serves as the essential trigger for synaptic vesicle release, and hypocalcemia (even mild) reduces the probability of neurotransmitter release. Furthermore, NMDA receptor-mediated calcium signaling, critical for long-term potentiation (LTP), is compromised in hypocalcemia, reducing synaptic strengthening during learning and memory consolidation. This represents a particularly important mechanism for cognitive impairment in deficient patients.

Neuroinflammation and Microglial Dysfunction: Emerging evidence indicates that vitamin D deficiency promotes a pro-inflammatory CNS environment through multiple mechanisms. VDR signaling in microglia and astrocytes suppresses TNF-α, IL-6, IL-1β production. Deficiency thus permits microglial activation, cytokine elevation, and neuroinflammatory cascade initiation. This neuroinflammatory state has emerged as a potential pathophysiological substrate for depression, anxiety, and cognitive impairment in vulnerable populations.

Neurotrophy and Synaptic Plasticity: Vitamin D upregulates nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF) expression in multiple CNS regions. These neurotrophic factors are essential for dendritic arborization, axonal sprouting, and synaptic density maintenance. Deficiency-induced reduction in neurotrophy may contribute to reduced hippocampal volume observed in some depression and neurodegenerative conditions.

Geriatric Populations

Older adults face compounded vitamin D deficiency due to reduced cutaneous synthesis capacity, decreased sun exposure, dietary insufficiency, reduced intestinal absorption, impaired renal 1α-hydroxylase activity, and increased medication-induced catabolism. Prevalence of deficiency exceeds 50% in community-dwelling older adults and approaches 80% in institutionalized populations. The clinical consequences in this age group encompass all previously discussed mechanisms while exhibiting accelerated progression:

• Accelerated bone loss: Deficiency-driven hyperparathyroidism produces more rapid osteoporosis with elevated fracture risk
• Muscle weakness and falls: Combined effects of myopathy and neurological dysfunction produce profound fall risk
• Cognitive impairment: Neuroinflammation, reduced neurotrophy, and vascular dysfunction converge to accelerate cognitive decline
• Mood disorders: Late-life depression associates strongly with vitamin D deficiency, particularly in winter months
• Cardiovascular disease: Deficiency associates with hypertension, endothelial dysfunction, and atherosclerotic disease progression
• Infectious disease susceptibility: Immune dysfunction from reduced VDR-mediated regulation of antimicrobial peptides (cathelicidin, β-defensin)

Fracture prevention is more limited than often assumed. In VITAL (LeBoff et al., NEJM 2022; n=25,871 generally healthy adults aged 50+), 2000 IU/day of vitamin D3 alone did not reduce total, nonvertebral, or hip fractures. Fracture benefit has been shown mainly when vitamin D is combined with calcium in deficient, frail, or institutionalized older adults; vitamin D alone, or intermittent very high doses, should not be expected to prevent fractures in replete community-dwelling adults.

Nuanced Pathophysiological Considerations: Beyond Simple Deficiency

Vitamin D pathophysiology extends substantially beyond classic deficiency disease, encompassing more subtle dysregulation of VDR signaling, genetic variation in vitamin D metabolism, and tissue-specific consequences of both deficiency and excess.

VDR Genetic Polymorphisms

Multiple polymorphisms in the VDR gene—including FokI, BsmI, ApaI, and TaqI variants—exhibit functional consequences for VDR expression and transactivation capacity. The FokI polymorphism, which results in VDR proteins differing by three amino acids, produces functional variants with differential transactivation efficiency. The 'F' allele lacks the upstream start codon and encodes the shorter 424-amino-acid protein, which is the more transcriptionally active receptor; the 'f' allele encodes a 427-amino-acid protein with roughly 1.7-fold lower transactivation activity in reporter assays.

It has been proposed that FokI genotype influences individual vitamin D requirements. It has been hypothesized that individuals with the less efficient 'ff' genotype may require higher circulating 25(OH)D levels to achieve VDR signaling equivalent to 'FF' carriers, although this has not been shown to change clinical dosing. This represents an important but often-overlooked source of inter-individual variation in vitamin D requirements and disease susceptibility. Some investigations suggest FokI polymorphisms influence psychiatric disease risk, though evidence remains preliminary.

The Calcium-Vitamin D Axis in Pathophysiology

Vitamin D deficiency pathophysiology is inextricably linked to calcium homeostasis in ways that complicate interpretation of single-nutrient effects. Chronic hypocalcemia, whether from vitamin D deficiency or primary hypoparathyroidism, produces similar psychiatric and neurological consequences. Conversely, some pathophysiological effects of vitamin D deficiency arise independent of serum calcium levels, suggesting VDR-mediated effects beyond calcium regulation.

This axis becomes clinically important when considering that deficiency can coexist with hypercalcemia in certain conditions (e.g., granulomatous diseases producing extra-renal 1,25(OH)2D), or conversely, adequate 25(OH)D levels may accompany hypocalcemia if renal 1α-hydroxylase is impaired. Clinical management thus requires assessment of both calcium and vitamin D status, not either alone.

Tissue-Specific VDR Signaling and Non-Classical Roles

Beyond VDR's canonical role in calcium-phosphate homeostasis, emerging evidence demonstrates tissue-specific VDR signaling with distinct physiological consequences. In lymphocytes, VDR activation promotes differentiation of naive T cells toward regulatory T cell (Treg) phenotype while inhibiting Th1 and Th17 differentiation. This immune-modulating effect occurs at VDR signaling levels substantially below those required for calcium regulation, suggesting that immune function may be more sensitive than skeletal effects to vitamin D deficiency.

In the parathyroid gland, VDR activation creates a negative feedback mechanism; deficiency permits unrestricted PTH synthesis and secretion, potentially leading to persistent hyperparathyroidism even after vitamin D repletion if secondary hyperparathyroidism has become autonomous. In bone, vitamin D's direct effects on osteoclast precursor differentiation through VDR may be as important as its indirect PTH-mediated effects.

The Paradox of Vitamin D Excess

While deficiency produces profound pathophysiological dysfunction, excessive vitamin D supplementation presents its own risks, though these are substantially less common than deficiency. Pharmacological vitamin D supplementation can produce hypercalcemia through two mechanisms:

• Saturated 24-hydroxylase: Very high 25(OH)D levels overwhelm CYP24A1 inactivation capacity, producing elevated 1,25(OH)2D
• Extra-renal 1α-hydroxylase: In granulomatous diseases, activated macrophages produce extra-renal 1,25(OH)2D that escapes normal feedback inhibition

Hypercalcemia from excessive vitamin D produces nephrolithiasis, vascular calcification, hypercalciuria, renal dysfunction, and potentially neuropsychiatric effects (lethargy, cognitive impairment, depression) distinct from deficiency effects. This risk, while uncommon, emphasizes that vitamin D exists within physiological bounds where both deficiency and excess produce dysfunction—a phenomenon termed the "vitamin D paradox."

Clinical and Pathophysiological Consequences of Untreated Vitamin D Deficiency

The consequences of persistent, untreated vitamin D deficiency extend across multiple organ systems with cumulative, often irreversible consequences:

Skeletal Consequences

Untreated vitamin D deficiency in adults produces progressive osteomalacia—a condition of impaired osteoid mineralization distinct from osteoporosis. Histomorphometric bone biopsy reveals increased osteoid thickness and delayed mineralization times. This process is often clinically silent until pathological fractures occur, frequently at unusual sites (femoral neck, pubic rami, sacrum). Some patients develop "looser's zones"—linear radiolucent bands on skeletal radiographs representing pseudofractures from stress within insufficiently mineralized bone.

The skeletal consequences of untreated deficiency in older adults include accelerated bone loss and increased fracture risk. In prospective studies, older adults with baseline 25(OH)D <20 ng/mL demonstrated bone mineral density loss 50-100% more rapid than those with adequate levels. Remarkably, this bone loss often persists despite adequate calcium intake, underscoring vitamin D's distinct role beyond simple calcium transport. The consequences manifest as increased hip, vertebral, and wrist fractures with substantial disability and mortality implications.

Muscular Weakness and Fall Risk

Untreated deficiency produces progressive proximal muscle weakness particularly affecting hip and knee extensors. The pathophysiology involves both direct VDR-mediated myopathic effects and indirect consequences of hypocalcemia. Type II muscle fiber atrophy, impaired calcium handling, and reduced ATP production converge to produce myopathy that may progress to severe disability. Fall frequency increases substantially in deficient older adults, with prospective studies demonstrating 30-50% increased fall risk with 25(OH)D <20 ng/mL.

The combination of impaired bone mineralization (osteomalacia) and severe myopathy creates a double vulnerability: weakened muscles cannot protect against falls, yet the skeleton's impaired mineralization lacks resilience to withstand trauma. This combination frequently leads to fractures that would not occur in similarly-aged individuals with adequate vitamin D status.

Psychiatric and Cognitive Consequences

Depression is consistently associated with low vitamin D. Observational studies report roughly 2-3 fold higher depression prevalence in individuals with 25(OH)D <20 ng/mL than in those with levels >30 ng/mL, but reverse causation (less time outdoors, poor diet, obesity, inactivity) and confounding are likely. Randomized evidence does not support a causal or treatment effect: in VITAL-DEP (Okereke et al., JAMA 2020; 18,353 adults aged 50+, 2000 IU/day vitamin D3 for a median 5.3 years), supplementation did not reduce incident or recurrent depression or change mood scores. Features sometimes described in depressed patients with deficiency (largely from small or uncontrolled studies) include:

• Prominent anhedonia and reduced reward sensitivity
• Motivational impairment and apathy
• Seasonal mood variation (seasonal affective disorder, SAD)
• Reported, but not established, poorer response to standard antidepressants
• Improvement with repletion in small trials and case series, not confirmed in large RCTs

Similarly, cognitive impairment in deficient older adults includes memory dysfunction, processing speed reduction, and accelerated cognitive decline. Prospective studies demonstrate greater cognitive decline in those with baseline deficiency; some investigations suggest that vitamin D repletion slows, and may partially reverse, cognitive decline, though evidence remains mixed. The mechanisms involve reduced neurotrophy, neuroinflammation, and impaired synaptic plasticity previously discussed.

Cardiovascular Consequences

Vitamin D deficiency associates with hypertension, atherosclerotic disease, endothelial dysfunction, and increased cardiovascular mortality. The mechanisms include VDR-mediated suppression of vascular inflammation, regulation of renin-angiotensin-aldosterone system (RAAS), and promotion of vascular calcification regulation. Deficiency permits unchecked RAAS activation through reduced suppression of renin transcription, contributing to hypertension in some patients. Additionally, deficiency-associated secondary hyperparathyroidism produces vascular calcification, particularly in chronic kidney disease patients, paradoxically increasing cardiovascular risk despite hypocalcemia.

Immune System Dysfunction

Untreated vitamin D deficiency produces profound immune dysfunction characterized by both impaired adaptive immunity and dysregulated innate immunity. VDR signaling in lymphocytes promotes Treg differentiation and suppresses pro-inflammatory Th1 and Th17 cells; deficiency thus permits unchecked inflammatory immune responses. Additionally, vitamin D upregulates antimicrobial peptides (cathelicidin, β-defensin) in epithelial and immune cells; deficiency reduces these innate immune defenses.

The clinical consequences include increased infection susceptibility, particularly to respiratory infections, and potentially worse outcomes from COVID-19 infection. Multiple observational studies demonstrate increased severe COVID-19 in vitamin D deficient populations, though randomized controlled trials testing supplementation during acute illness have shown mixed results. The deficiency also associates with autoimmune disease exacerbation, potentially through loss of regulatory immune tolerance.

Treatment Approaches: Dietary Sources, Supplements, and Medications

Dietary Sources and Natural Vitamin D

Few foods naturally contain substantial vitamin D. Oily fish (salmon, mackerel, herring) provide 400-1000 IU per 3.5-ounce serving; egg yolks provide approximately 20-40 IU per egg; mushrooms exposed to sunlight produce ergocalciferol (vitamin D2) through UVB-induced conversion. For comparison, the Recommended Dietary Allowance (RDA) is 600-800 IU daily for most adults, with higher recommendations (800-1000 IU) for older adults 71 years and above. Notably, the RDA is set to prevent frank deficiency disease (osteomalacia, rickets) rather than optimizing circulating 25(OH)D levels for psychiatric or immune benefits.

Food fortification programs—particularly milk and dairy product fortification in North America—contribute substantially to population vitamin D intake. In the United States, fortified milk contains 100 IU per cup; fortified orange juice contains 100 IU per cup. However, these modest amounts prove insufficient to correct established deficiency or maintain optimal levels in populations with minimal sun exposure.

Supplemental Vitamin D: Forms, Dosing, and Bioavailability

Vitamin D supplementation exists in two primary forms: vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). These differ in source and metabolism:

Multiple meta-analyses and randomized controlled trials demonstrate that vitamin D3 is superior to D2 for raising and maintaining circulating 25(OH)D levels. At equivalent doses, vitamin D3 produces 1.5-2 fold greater elevation in 25(OH)D compared to D2. This superiority reflects more efficient hepatic activation of D3 due to higher affinity for the 25-hydroxylase enzyme. For deficiency correction and maintenance, vitamin D3 is the preferred form.

Dosing strategies for correcting vitamin D deficiency vary by severity and clinical context. General recommendations include:

• Insufficiency (20-30 ng/mL; benefit of treatment uncertain, and not treated as deficiency under IOM thresholds): 1000-2000 IU daily or 50,000 IU weekly for 8 weeks, then maintenance with 1000-2000 IU daily
• Moderate deficiency (10-20 ng/mL): 50,000 IU weekly for 8-12 weeks, then maintenance with 2000-4000 IU daily
• Severe deficiency (<10 ng/mL): 50,000 IU weekly for 12+ weeks, then maintenance, with reassessment for secondary hyperparathyroidism

Absorption of vitamin D supplements is enhanced by consumption with dietary fat; supplementation on an empty stomach or with fat-free meals substantially reduces bioavailability. Standard capsules and tablets are absorbed adequately; liquid formulations may enhance absorption in patients with fat malabsorption.

High-Dose Vitamin D Therapy and Safety Considerations

The tolerable upper intake level (UL) for vitamin D was set at 4000 IU daily for adults by the Institute of Medicine (now the National Academies) in 2011. The 2011 Endocrine Society guideline suggested 1500-2000 IU daily for adults at risk of deficiency, but it has been replaced by the 2024 Endocrine Society guideline, which suggests against empiric supplementation above the RDA (600 IU daily to age 70, 800 IU over 70) in healthy adults under 75, suggests empiric supplementation for ages 1-18, adults 75 and older, pregnancy, and high-risk prediabetes, and advises against routine 25(OH)D testing in these groups. Treatment of documented deficiency or of established indications (e.g., malabsorption, osteoporosis care) is outside that guideline's scope, and higher doses remain appropriate there. Importantly, toxicity is extraordinarily rare at doses under 10,000 IU daily in individuals without granulomatous disease. The vitamin D3 doses used therapeutically (50,000 IU weekly) are substantially below toxic thresholds.

Monitoring during high-dose therapy should include baseline and follow-up serum calcium, urinary calcium, and renal function assessment. If serum calcium rises above 10.5 mg/dL or 24-hour urinary calcium exceeds 300 mg, supplementation should be reduced. Most commonly, 25(OH)D is measured 8-12 weeks after initiating supplementation to assess adequacy of dosing and guide maintenance therapy.

Topical and Activated Vitamin D Preparations

Beyond oral supplementation, two categories of topical vitamin D preparations exist:

Topical Vitamin D Analogs: Calcipotriene and calcitriol creams are utilized for psoriasis and other dermatological conditions. These penetrate skin to activate VDR, reducing keratinocyte proliferation and promoting differentiation. Systemic absorption is minimal with topical application, making these preparations safe without risk of hypercalcemia. Efficacy is local; these do not correct systemic vitamin D deficiency.

Oral Active Metabolites: Calcitriol (1,25(OH)2D) is a pharmaceutical form of the active hormone utilized in specialized circumstances: hypoparathyroidism, severe renal disease with impaired 1α-hydroxylase function, and vitamin D-dependent rickets type 1 (defective CYP27B1). Dosing is typically 0.25-0.5 mcg twice daily, with careful monitoring for hypercalcemia due to the potency of the active metabolite. Calcitriol is inappropriate for correcting simple vitamin D deficiency in individuals with intact renal function, as the kidneys cannot appropriately downregulate 1,25(OH)2D production in response to supplementation, risking hypercalcemia.

Medication Interactions and Vitamin D Metabolism

Multiple medications significantly alter vitamin D metabolism and requirements:

Patients on anticonvulsant therapy deserve special mention, as this population exhibits particularly high deficiency rates. Phenytoin, phenobarbital, and carbamazepine all induce hepatic CYP450 enzymes, accelerating both 24,25(OH)2D and 1,25(OH)2D catabolism. Patients on these medications often require vitamin D supplementation 3-4 times higher than non-medicated individuals. Paradoxically, some of these patients develop hypercalcemia despite deficiency, reflecting mobilization of skeletal calcium through secondary hyperparathyroidism in the setting of inadequate vitamin D-mediated intestinal calcium absorption.

Vitamin D Testing and Monitoring Strategy

Serum 25(OH)D represents the gold standard for assessing vitamin D status, reflecting both cutaneous synthesis and dietary intake over the preceding 8-12 weeks. Circulating 1,25(OH)2D should not be used for assessment of vitamin D status, as it is tightly regulated and may remain relatively normal or even elevated in deficiency states due to secondary hyperparathyroidism.

Interpretation of 25(OH)D levels:

• <12 ng/mL: Deficiency (risk of osteomalacia, rickets) (IOM)
• 12-20 ng/mL: Potentially inadequate for bone health in some people (IOM)
• 20-30 ng/mL: Adequate for bone health in most people per IOM; labeled "insufficiency" by the 2011 Endocrine Society guideline
• 30-100 ng/mL: Replete; no proven added benefit from targeting this range in healthy people (the 2024 Endocrine Society guideline endorses no specific target)
• >100 ng/mL: Excess (risk of toxicity, hypercalcemia)

Initial assessment of deficient patients should include PTH, serum calcium (albumin-corrected), phosphate, and renal function. Elevated PTH with low-normal serum calcium in the setting of low 25(OH)D confirms secondary hyperparathyroidism. When treating documented deficiency, reassessment at 8-12 weeks confirms repletion. A level of at least 20 ng/mL is adequate for bone health in most people (IOM), and osteoporosis guidelines commonly aim for at least 30 ng/mL. The 2024 Endocrine Society guideline does not endorse any specific target level, and there is no evidence supporting higher targets (e.g., 40-60 ng/mL) for psychiatric indications.

Evidence-Based Clinical Algorithm for Vitamin D Deficiency Management

Figure 3: Evidence-based diagnostic and therapeutic algorithm for vitamin D deficiency management

Summary and Clinical Recommendations